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Corticosteroids are broadly active and potent anti-inflammatory agents that, despite the introduction of biologics, remain as the
mainstay therapy for many chronic inflammatory diseases, including inflammatory bowel diseases, nephrotic syndrome,
rheumatoid arthritis, chronic obstructive pulmonary disease and asthma. Significantly, there are cohorts of these patients with
poor sensitivity to steroid treatment even with high doses, which can lead to many iatrogenic side effects. The dose-limiting
toxicity of corticosteroids, and the lack of effective therapeutic alternatives, leads to substantial excess morbidity and healthcare
expenditure. We have developed novel murine models of respiratory infection-induced, severe, steroid-resistant asthma that
recapitulate the hallmark features of the human disease. These models can be used to elucidate novel disease mechanisms and
identify new therapeutic targets in severe asthma. Hypothesis-driven studies can elucidate the roles of specific factors and
pathways. Alternatively, 'Omics approaches can be used to rapidly generate new targets. Similar approaches can be used in other
diseases.
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ASTHMA
The prevalence of asthma has been increasing globally over the past
three decades. There is an estimated 300 million people suffering the
disease worldwide, with 1–18% of the population affected depending
on the countries involved.1 In Australia, 410% of the population
suffers from asthma.2 This disease imparts a large healthcare burden
costing $58 billion per year in the USA, Europe and Australia.3
Asthma is characterised by airway inflammation, remodelling and
hyperresponsiveness (AHR). Chronic mild to moderate asthma
involves frequent recurrent exacerbations of eosinophil-mediated
immunopathological processes inducing hallmark symptoms such as
coughing, wheezing, dyspnoea and tightening of the chest in response
to bronchoconstriction.4,5 Asthma severity is clinically characterised
according to symptoms and with impaired lung function as a lower
than predicted forced expiratory volume in 1 s (FEV1). Mild to
moderate asthmatics have intermittent symptoms with exacerbations
2–7 times per week and a baseline FEV1 of 60–80% predicted. Severe
asthmatics have multiple exacerbations per day with one hospitalisa-
tion in the previous year, a baseline FEV1 of o60% predicted, poor
symptom control and worsening symptoms with tapering of
corticosteroids.4–6
Corticosteroids and bronchodilators are used in combination to
control symptoms and improve lung function. These therapies are
highly effective in patients with mild to moderate eosinophilic
asthma.4,5 However, a large population-based survey within Australia
highlighted that almost 45% of patients had either uncontrolled
symptoms despite good self-reported adherence to medication or
uncontrolled symptoms with no preventer or poor adherence.7 In
larger studies, figures show that between 10 and 15% of asthmatics are
refractory to corticosteroids even with high-dose therapy and their
symptoms are not well managed despite adherence to currently
available medication. These patients are said to have severe, steroid-
resistant (SSR) or insensitive (SSI) asthma, and typically have a non-
eosinophilic-associated disease profile in contrast to the classic
eosinophil-dominated response. This form of asthma is currently
the major unmet clinical need in regard to asthma pathology.8
This review aims to provide (1) a background of the immuno-
pathological processes behind an example disease in asthma,
(2) a description of current therapies and how severe asthma
differs, (3) discuss potential mechanisms driving severe asthma, and
(4) demonstrate how murine models can be utilised in the discovery
of novel mechanistic or functional targets for the development of
therapeutic interventions for this difficult-to-treat form of asthma, and
other diseases.
PATHOLOGY OF ASTHMA
In asthma, insults to the respiratory epithelium induce the release of
pro-inflammatory mediators that cause inflammatory cell influx.9 The
infiltration of inflammatory cells initiates the additional release of cell
mediators that contribute to narrowing of the bronchial lumen and
mucus-secreting cell hyperplasia leading to pulmonary oedema and
subsequent vascular leakage.10,11 These events lead to AHR and airway
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obstruction.4,5 Repeated insults lead to cycles of injury that results in
the remodelling of airways characterised by collagen deposition,
epithelial membrane thickening, increased airway smooth muscle
(ASM) mass, and scar formation within the basement membrane,
which is characteristic of chronic asthma.12,13
Eosinophilic mild to moderate asthma
T helper lymphocyte type (Th)2 cell-mediated, eosinophilic allergic
asthma affects approximately half of the asthmatic population.14
Although it is more pronounced in mild to moderate asthmatics, it
is also present in persistent, moderate to severe asthmatics.15 It is
associated with the excessive production of Th2 cytokines, interleukin
(IL)-4, IL-5, IL-13, and eosinophilic inflammation in the airways upon
subsequent exposure to aeroallergens. Eosinophilic asthma is defined
by high sputum eosinophil levels with macrophage and neutrophil
levels equivalent to healthy individuals.16
The process of disease development is not well understood, but is
thought to occur through abnormal signalling events leading to the
differentiation of naïve T helper (Th0) cells into antigen-specific
effector and memory Th2 cells.4,5,17 Normally innocuous environ-
mental antigens are captured by dendritic cells, fragmented and
presented to naive CD4+ T helper lymphocytes in lung draining lymph
nodes.18 Under normal non-pathological conditions (Figure 1), this
leads to the maturation of tolerogenic regulatory T helper cells (Tregs).
However, in allergic asthma, antigen presentation drives the develop-
ment of antigen-specific Th2 cells. These Th2 cells release pro-
inflammatory Th2 cytokines, IL-4, IL-5 and IL-13, which are involved
in the activation and differentiation of immunoglobulin (Ig) class
switching and production of IgE antibodies from B lymphocytes.19,20
Increased levels of extracellular IgE are correlated with the severity of
allergic sensitisation involving bronchial hyperresponsiveness,21 in
which it readily reacts with Fcε receptors on the surface of
inflammatory mast cells to activate them and cause subsequent
degranulation to release histamines and prostaglandins.22 This leads
to increased vascular permeability, vascular leakage, oedema and AHR.
IL-13 is involved in the chemoattraction and activation of eosinophils,
IgE class switching on B cells, and induction of AHR and mucus
hyper-secretion.23,24 Clinically, IL-13 has been shown to induce both
AHR and mucus secretion, which interestingly, is suppressed in both
humans and mice by IL-13 antibody neutralisation.25,26
Non-eosinophilic endotypes of asthma
The mild to moderate asthmatics with eosinophil-rich airway inflam-
mation (described above) are termed eosinophilic asthmatics. Research
over the past decade has shown that distinct asthma phenotypes exist
that are characterised by neutrophil and/or macrophage-dominated
inflammation and increased Th1 and/or Th17 associated responses.
Up to 25% of asthmatics have high sputum neutrophil levels with low
to normal levels of eosinophils, and are described as neutrophilic
asthmatics.16 As many as one-third of all asthmatics have higher than
average macrophage levels with no change in neutrophils or eosinophils,
and are referred to as paucigranulocytic asthmatics.27 Mixed granulo-
cytic asthmatics are those with high-sputum neutrophil and eosinophil
numbers.23 Patients with non-eosinophilic asthma typically are older
and have more severe disease that is resistant to steroid therapy.
Importantly, non-eosinophilic endotypes of asthma are associated with
increased innate immune responses including increased CXCL8/IL-8
expression, and toll-like receptor (TLR)-2 and TLR-4 activity (Figure 2).
CXCL8 is involved in the chemoattraction and activation of neutrophils,
and TLRs respond to pathogen-associated molecular patterns (PAMPs)
on the surface of pathogens. Interestingly, TLR-2 and TLR-4 orchestrate
the infiltration of neutrophils and macrophages during inflammation,
and initiate Th1/Th17-associated, pathogen-targeted adaptive immune
responses.28,29
The role of neutrophils and macrophages in the pathogenesis of
non-eosinophilic asthma is not fully understood, but may involve the
release of pro-inflammatory cytokines, including IL-1β, interferon
(IFN)-γ and tumour necrosis factor (TNF)α. New evidence suggests
that the NLRP3 inflammasome may be an important driver of these
SSR forms of asthma.30,
Late onset and severe forms of asthma have been associated with
incompletely reversible airway obstruction and a mixed Th1/Th17
cytokine profile.31,32 Increased Th1/Th17 cytokine expression
correlates with increased neutrophils in asthmatic patients32 and
Figure 1 Inflammatory pathways in typical allergic asthma. Environmental allergens can stimulate dendritic cells (DCs), which in turn activate naïve CD4 T
helper 0 (Th0) cells. These can differentiate into Th1, Th2, Treg, Th17 cells depending on the cytokine environment. A plethora of cytokines are then
secreted including; IL-5 that activates eosinophils; IL-4 and IL-13 that activate B cells. B cells can then release IgE that acts on mast cells to release
histamine and prostaglandins and other mediators.
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severe, neutrophilic asthma is characterised by extensive tissue
remodelling.32,33 Surprisingly, clinical trials assessing the efficacy of
the anti-IL-17 receptor A antibody, Brodalumab, showed no signifi-
cant clinical benefit in moderate to severe asthmatics.34 Clinical and
experimental evidence has identified that the Th2 cytokines, IL-4 and
IL-13, increase Th17-driven inflammation.35 Thus, blockade of both
Th2 and Th17 cytokines may provide synergistic therapeutic benefit in
some patients.
SSR asthma
The situation with SSR asthma is complex and there is variation in
how individual studies describe populations of non-eosinophilic,
neutrophilic, and SSR or SSI asthma. The majority of SSR asthmatics
have predominantly neutrophilic inflammation and many neutrophilic
asthmatics have steroid-resistant disease. We discuss the relevant
studies according to how individual study populations were described.
Structural changes in asthma have been shown to be associated with
Th2-mediated eosinophilic inflammation, rather than Th1/Th17-
associated neutrophilic inflammatory responses.36 However, the
degree of airway remodelling is directly correlated with asthma
severity, and severe asthma is predominantly non-eosinophilic, with
increased Th1/Th17-associated responses and sputum neutrophils.31,37
Together, these data suggest that the mechanisms underpinning severe
asthma are multifactorial, including resistance to steroid treatment.
Steroid-resistant asthma is defined as the inability to achieve greater
than 15% improvement in FEV1 following a seven day course of
20 mg per day prednisone or equivalent corticosteroid.38 These
patients have a poor quality of life owing to a reduced ability
to perform simple daily tasks, such as walking up flights of stairs,
and frequency of hospitalisation.6 Steroid-resistant asthmatics
disproportionately contribute to over 50% of total healthcare costs
associated with the disease. Importantly, SSR asthma is strongly
associated with infection (see below) and up to 50% of patients are
obese.39,40
CURRENT ASTHMA THERAPIES AND LIMITATIONS
Glucocorticoids and β-adrenoceptor agonists
The primary objective of current asthma therapies is to reduce
symptoms and prevent exacerbations of the disease without
necessitating emergency department visits and/or hospitalisations. In
most patients, asthma is controlled, and exacerbations prevented,
through combined therapy with inhaled corticosteroids and long-
acting β-agonists (LABAs).41,42 Although the symptomatic relief of the
onset of asthma symptoms is through administration of short-acting
β-agonists (SABAs), corticosteroids are used to reduce inflammation
through the suppression of pro-inflammatory gene transcription.43
Inhaled corticosteroids comprised of glucocorticoids act through
the binding of glucocorticoid receptors (GR).42 Activation of the
GR results in increased expression of anti-inflammatory genes,
decreased expression of pro-inflammatory genes and non-genomic
mechanisms.44 Binding of glucocorticoids to intracellular GRα,
complexed with heat shock proteins and immunophilins, leads to a
conformational receptor change allowing nuclear trans-localisation.
Two GR proteins interact to form a homodimer and bind to DNA at
glucocorticoid response elements located within the regulatory regions
of glucocorticoid responsive genes and act as enhancer elements,
leading to the transcription of anti-inflammatory genes.43 Direct anti-
inflammatory effects are most likely due to glucocorticoid-induced
repression of pro-inflammatory and immune genes that are normally
activated by the transcription factors nuclear factor-κB and
Figure 2 Inflammatory pathways in severe, steroid-resistant (SSR) asthma. In SSR asthma insults such as respiratory infection can lead to increased
neutrophilic inflammation. Neutrophils contribute to increased airway hyperresponsiveness (AHR), goblet cell hyperplasia, changes in airway smooth muscle
(ASM) phenotype and increased angiogenesis. In addition, increases in Th1 and Th17 cell numbers, and decreases in autophagy, also occur. Increased levels
of glucocorticoid receptor (GRβ) can inhibit GRα, and reactive oxygen species (ROS) can decrease histone deacetylase (HDAC)-2 levels leading to impaired
corticosteroid activity.
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activating protein-1.8 The additional anti-inflammatory actions of
glucocorticoids are broad as they have indirect effects that include the
downregulation of a number of cytokines, adhesion molecules,
enzymes, and receptors such as GRβ.45 Therefore, glucocorticoids
are both directly and indirectly responsible for inhibiting the devel-
opment, infiltration, and activation of a variety of immune cells
involved in airways inflammation, including macrophages, T cells,
eosinophils and airway epithelial cells. These broad effects allow
glucocorticoids to not only suppress airway inflammation, but also
reduce subsequent effects on AHR and lumen narrowing.43
There are numerous issues with steroid treatments. Their efficacy
wanes over time, there are side effects of long term use (for example,
osteoporosis) and issues with inhaler use and delivery, and people
naturally do not like taking steroids (for example, pregnant women).
Furthermore, steroid therapy temporarily alleviates the symptoms of
disease and is not a cure. Therefore, not surprisingly, there are a
plethora of new therapies being tested for allergic asthma that attempt
to provide long terms benefits, such as targeted therapeutics in the
form of monoclonal antibodies (for example, against Th2 cytokines,
IL-4, IL-5 and IL-13, Figure 1) (reviewed in refs 4 and 5). This
includes clinical trials of the IL-4 receptor antagonist, Dupilumab. One
study showed improved lung function, reduced levels of Th2-
associated inflammatory markers and fewer asthma exacerbations in
a specific patient group of persistent, moderate to severe asthmatics
with elevated eosinophils.15 There are a wide range of other avenues
that are being investigated such as the induction of Treg responses
with bacterial components.46–50
There are currently no other effective treatments for SSR asthma.
Macrolides are antibiotics that also have anti-inflammatory properties,
which have been shown to be effective in experimental models and
may, therefore, have beneficial effects in chronic respiratory disease.
These are currently in clinical trials.51,52 Elucidating the mechanisms
involved in the pathogenesis of SSR asthma may identify new
therapeutic targets.
MECHANISMS OF PATHOGENESIS OF SSR ASTHMA
The development of new therapies is facilitated by improving our
understanding of the underlying mechanisms that promote disease
pathogenesis. SSR and SSI asthma are multifactorial and elucidating
the pathogenesis of these forms may identify novel therapeutic targets.
Potential factors include oxidative stress, altered immune responses,
impaired autophagy, angiogenesis, changes in ASM phenotype and
respiratory infections (Figure 2).
Increased oxidative stress and mitochondrial dysfunction
Oxidative stress may be induced by free radicals that induce reactive
oxygen species (ROS), and is strongly associated with inflammatory
responses in the airways in asthma.53,54 Mitochondrial dysfunction may
also contribute to production of ROS and has been observed in both
human and mouse asthmatic bronchial epithelial cells.55,56 Increases
in mitochondrial respiratory complex III mediates higher production
of ROS57 and treatment with mitochondrial-targeted antioxidant
(mitoTEMPO) neutralised mitochondrial ROS in both mouse and
cultured human epithelial cells.58 In ovalbumin-induced allergic airways
disease (AAD), mitochondrial dysfunction was also evident by reduced
expression of cytochrome c oxidase and complex I,55 with function
restored with anti-IL-4, but not anti-IFNγ, monoclonal antibodies.
In regard to steroid resistance, ROS has a suppressive effect on
steroid efficacy. This most likely occurs by reducing functional
HDAC-2 activity and dampening of its anti-inflammatory effects that
occur during GR signalling.59 By combating oxidative stress with the
use of antioxidants it may be possible to reverse these effects and
increase glucocorticoid efficacy, making disease more manageable.
Altered immune factors
Th1- and Th17-dominated responses seen in SSR asthma are
associated with induction of pro-inflammatory cytokines such as
IL-1β and TNFα. It is likely that increased production of these factors
leads to the induction of inflammatory responses that are unrespon-
sive to steroid treatment. Increased expression of IL-1β has been
associated with a refractory response to steroid therapy alongside
TNFα in a number of inflammatory conditions.39,60 A single study has
assessed the effects of the blocking IL-1β with the monoclonal
antibody, Canakinumab (ACZ885), in mild to moderate
asthmatics.61 This study with a small patient cohort (n= 21), demon-
strated that ACZ885 significantly attenuated the late asthmatic
response to allergen by 28%.61 An additional phase I clinical trial
assessed the IL1R antagonist, Anakinra, which blocks the receptor for
both IL-1α and IL-1β, in healthy subjects treated with inhaled
lipopolysaccharide to induce a neutrophilic response. Subcutaneous
administration of Anakinra significantly decreased neutrophilia, IL-1β,
IL-6 and IL-8 levels without increasing the rate of infections.62 Work
from Stampfli63 and others64 has demonstrated that sensitisation to
house dust mite (HDM) is dependent on IL-1α and not IL-1β in
mouse models and is supported by clinical evidence of ACZ885 and
Anakinra in patients. However to date, no studies have assessed IL-1β
monoclonal antibodies or Anakinra in SSR asthma or via different
routes of administration.
In addition, GRβ is known to inhibit the activation of anti-
inflammatory genes by GRα when present in high concentrations.65
TNFα enhances GRβ expression, and both factors have been identified
in steroid-resistant asthma.45,66 Interestingly, a recent study has shown
anti-TNFα therapy reduced steroid resistance in an animal model of
asthma, but clinical trials have been stopped as a result of increased
susceptibility to infection.4 There may be a synergistic interaction
between IL-27 and the archetypal Th1 cytokine IFNγ that
induces steroid-resistant AHR by inhibiting glucocorticoid signalling
in macrophages, as shown in experimental models.67
Impaired autophagy
Autophagy is a normal homeostatic process that clears proteins in a
cell. Recent evidence has shown that diminished autophagy leads to
increased steroid-resistant AHR and neutrophilic inflammation in
mice in an experimental model of HDM-induced AAD.68 This
increased neutrophilic inflammation was associated with impaired
autophagy in pulmonary CD11c+ cells.68
Increased angiogenesis
Angiogenesis is a prominent feature of airway remodelling that
occurs in asthmatic airways in which expansion in blood vessel
formation, accompanied by fibrosis of inflamed tissue, leads to further
aggravation of chronic inflammation.69 It is currently unknown
whether inflammation leads to remodelling or vice versa, however,
it is clear these two processes influence the outcome of chronic
asthma. Reducing angiogenesis through endogenous inhibitors may
result in the reduction of accompanying airway inflammation and
fibrosis that contribute to AHR. For example, collagen IV is found
to be decreased in the airway basement membrane in asthma.70 The
non-collagenous domain-1 α3 chain of collagen IV is an endogenous
anti-angiogenic agent known as tumstatin, and is depleted in
asthmatic airways.69 Use of recombinant tumstatin, and synthetic
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tumstatin-derived peptides, inhibits angiogenesis, inflammation and
suppresses AHR in murine models.69,70
Changes in ASM phenotype
Narrowing of the airways, although multifactorial, is strongly asso-
ciated with ASM abnormalities. ASM cells are thought to contribute to
the pathogenesis of asthma by providing a link between airway
inflammation and remodelling, and they are the major controllers of
bronchoconstriction.71,72 ASM contraction (Figure 3) begins with a
contractile agonist, such as histamine, binding to its G protein-coupled
receptor. This interaction activates phospholipase C (PLC), and the
Ca2+-oscillation pathway forming inositol triphosphate (IP3) through
phosphatidylinositol biphosphate (PIP2) hydrolysation. IP3 binds to its
receptors on the sarcoplasmic reticulum membrane, releasing intra-
cellular calcium ions (Ca2+).73 Ca2+ forms a complex with calmodulin,
activating myosin light chain kinase (MLCK), which phosphorylates
regulatory myosin light chains forming phosphorylated-MLC
(p-MLC). This activates actin and myosin cross-bridges, resulting in
shortening and contraction of ASM cells.74 Ca2+ returns to homoeo-
static levels through plasma membrane Ca2+ ATPase pumps, uptake
by mitochondria, and reuptake into the sarcoplasmic reticulum by
action of sarco/endoplasmic reticulum Ca2+ ATPase. In addition,
Ca2+-sensitisation can occur whereby signalling through the agonist
receptor activates protein kinase C or Rho-activated kinase pathways,
leading to phosphorylation of myosin light chain phosphatase
(MLCP). Once MLCP is phosphorylated, it is unable to depho-
sphorylate MLC, making the contractile apparatus more sensitive to
Ca2+ from the Ca2+ oscillation pathway. Although the understanding
of Ca2+ signalling is established in healthy ASM, changes to
ASM under disease conditions are less well understood.75 A greater
understanding of these mechanisms that underpin hyper-contractility
and airway remodelling due to ASM abnormalities, and its subsequent
effect on steroid resistance in severe asthma, could provide more specific
targets to reverse steroid resistance and/or increase steroid sensitivity.
Respiratory infections
Although a number of mechanisms have been identified that may have
a role in driving SSR asthma, many studies demonstrate a strong link
between respiratory infections and the pathogenesis of the disease.
Chlamydia pneumoniae is linked clinically and experimentally with
the induction and development of asthma, particularly severe asthma,
in children and adulthood.76–82 In asthmatics with evidence of
previous Chlamydia infection (elevated Chlamydia-specific serum
IgE, IgG and IgA), disease tends to be more severe, with more
frequent acute exacerbations, and increased neutrophilia.77,83 In
relation to steroid resistance, asthmatics requiring high-dose steroid
therapy are more likely to have evidence of Chlamydia infection,
compared with those on low dose steroid therapy.84 Furthermore,
increased airway neutrophilia, along with high-dose steroid treatment,
has been shown to predict the presence of respiratory Chlamydia
infection in a cohort of adolescent asthmatics.83 Chlamydia is able to
infect immune cells altering their function and promoting the
development of AAD.85,86
Haemophilus influenzae is commonly isolated from the lungs of
severe, neutrophilic asthmatic patients that are refractory to steroid
therapy.87 Increased neutrophil levels during H. influenzae infection
correlates with decreased lung function, and increased airway
obstruction and IL-8 responses.87 Importantly, H. influenzae respira-
tory infection in murine models of asthma has been shown to induce
an inflammatory phenotype resembling neutrophilic asthma that is
IL-17 dependent.88,89
Asthmatics with viral infections (i.e. rhinovirus, respiratory syncytial
virus and influenza) have increased exacerbations, significantly
reduced FEV1, and increased neutrophilic inflammatory responses
compared with non-infected asthmatics.90,91 These features and virus-
exacerbated wheeze do not respond to steroid therapy.92 Elucidating
the effect of respiratory infections on the asthmatic lung may uncover
the mechanisms that underpin the pathogenesis of steroid resistance,
and highlight novel therapeutic targets for this form of the disease.
ASSESSMENT OF THE PATHOGENESIS OF SSR ASTHMA
Animal models of steroid-resistant asthma
To uncover the mechanisms linking respiratory infection with SSR
asthma, we have sought to model this association. This has led to the
development of murine models that recapitulate the key features
(airway inflammation and AHR) of human asthma, termed AAD
(Table 1).51,88,93 We then established Chlamydia, H. influenza and
influenza respiratory infections. These models have the hallmark
features of infection. We then combined them to show that
infection induced SSRAAD.80,88,89 Clinical studies indicate that it is
infections in established asthma that drive more severe disease and
steroid resistance. Thus, we refined our models so that AAD is first
established and then respiratory infection is induced, which better
models the human scenario.51 Mice are sensitised with Ova and alum
(d0, 50 μg Ova, intraperitoneally (i.p.)), followed by Ova challenge
(d12–13, 10 μg Ova, intransally (i.n.)) to induce acute AAD. Mice are
left for 20 days and then re-challenged (d33–34, 10 μg Ova, i.n.). This
represents an exacerbation of established disease. AAD is assessed
1 day after the final challenge (d35). To induce SSR disease mice are
Figure 3 Airway smooth muscle contraction. Bronchoconstriction occurs
when intracellular Ca2+ levels and Ca2+ sensitivity are increased. Ca2+
release from the sarcoplasmic reticulum, either through IP3 or Ca2+
activation of the IP3R or RyR, respectively, increases intracellular Ca2+ to
activate CaM and MLCK, resulting in the phosphorylation of MLC and
subsequent contraction. Ca2+ oscillations contribute to this contraction,
whereby intracellular Ca2+ is released via IP3 or RyR or taken up into the
sarcoplasmic reticulum through SERCA. CaM, calmodulin; [Ca2+]i,
intracellular calcium; IP3, inositol trisphosphate; MLC, myosin light chain;
MLCK, myosin light chain kinase; MLCP, myosin light chain phosphatase;
RyR, ryanodine receptor; SERCA, sarco/endoplasmic reticulum Ca2+-ATPase.
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infected after AAD is established (d14) but before re-challenge. Some
groups are treated with dexamethasone (DEX; d32–34, 2 mg kg− 1 in
PBS, i.n.). Infection suppresses eosinophilic and Th2-associated
responses whilst increasing neutrophilic airway inflammation and
Th1/Th17-associated responses. It also results in steroid resistance of
inflammation and AHR in AAD. Thus, infection induces severe
neutrophilic AAD that is steroid-resistant (SSRAAD; Table 1). The
effects of each of these three infections on an AAD model results in
different immune and inflammatory profiles that represent different
subsets of SSR asthma observed clinically, including neutrophilic and
eosinophilic subsets. Chlamydia infection leads to an increase in
neutrophilic, and a decrease in eosinophilic, airway inflammation. It
also increases the expression of Th1- and Th17-associated cytokines.
Haemophilus infection also leads to an increase in neutrophilic
inflammation, and a decrease in eosinophilic inflammation, while
increasing the expression of Th17-associated cytokines. Influenza
infection does not alter neutrophilic or eosinophilic inflammation,
but does increase the expression of Th1-associated cytokines. We have
also infected neonatal mice with these pathogens and then induced
AAD in later life. These early life infections also increase the severity of
AAD and induce steroid resistance of key disease features. The over-
arching feature of steroid-resistant AHR and inflammation in each of
the three infection models suggests that they are a valuable platform
for the investigation of universal mechanisms of steroid resistance.
Factor-targetted studies
These and other models of SSR asthma can be used in traditional ways
to explore the contributions of specific factors of interest. Their levels
can be measured and factor-deficient or -overexpressing mice with
SSRAAD can be assessed compared to wild-type and control mice.
Furthermore, targeted interventions with siRNA, antibodies or
potential new drugs can be used to intervene in candidate processes
to elucidate their roles and potential for therapeutic targeting. Using
such approaches roles have been identified for neutrophils and
macrophages, IL-13, IL-17, IL-27/IFNγ and microRNAs (miRNAs)
in SSRAAD in adulthood,67,80,86,89,94–97 and bone marrow changes,
IL-13, TRAIL and PD-1 in early life infection-induced disease.98–101
Microarray, RNA-Seq and discovery-driven studies
A large body of evidence indicates that functional abnormalities may
be broadly important in the development of steroid resistance in
chronic inflammatory diseases, including asthma. However, as each
disease is characterised by a unique set of pathogenic mechanisms it is
likely that the processes that lead to steroid resistance are context-
dependent and many different processes may be involved. Thus, novel
discovery and global ‘Omics studies are valuable in identifying
new factors and the elucidation of multi-component pathways.
Genome-wide association studies utilise rapidly scanning markers
across multiple sets of DNA, or genomes, to find genetic variations
associated with a disease. Genetic predisposition may have a role in
steroid resistance in asthma, and so genome-wide association studies
can be used to identify any variations that underpin this.102,103
Previously, susceptibility loci/genes in severe asthma have been
identified (ORMDL3/GSDMB, IL1RL1/IL18R1)103 but few, if any,
represent targets for therapeutic strategies with real-world applications.
Functional genomics uses data gained from genomic projects to
describe gene (and subsequently protein) function and interaction.
This field of molecular biology has been used to undertake discovery-
driven research regarding asthma pathology. This is a powerful tool,
finding novel factors, mechanisms and pathways involved in different
disease states. DNA microarrays have been used to advance our
understanding of the mechanisms that underpin abnormalities in
asthma pathology, showing their capacity to accelerate the discovery
process and provide a more complete understanding of the molecular
basis of disease.104 Quantitative detection of reverse-transcribed RNA
transcripts in many studies has shown that microarray-based profiling
can identify novel factors that are altered within the disease. Also, gene
expression (GEx) microarray is a well-established, high-throughput
Table 1 Mouse models of steroid-resistant asthma
Reference Mouse
strain
Experimental protocol Outcomes
93 Balb/C Sensitisation OVA i.p. −21 days,
−7 days; aerosolized OVA 3 days per
week, 4 weeks
cf. Saline
↑ Eosinophils,
↑ Neutrophils
93 Balb/C Sensitisation OVA i.p. −21 days,
−7 days; aerosolized OVA 3 days per
week, 4 weeks; dexamethasone 24 h
and 2 h before last challenge
cf. OVA
↓ Eosinophils,
↑ Neutrophils
68 C57Bl/6 Sensitisation HDM intranasal d1; HDM
intranasal d8, d15
cf. Saline
↑ AHR,
↑ Eosinophils,
↑ Neutrophils
68 C57Bl/6 Dexamethasone d1; sensitisation HDM
intranasal d1; HDM intranasal d8, d15
cf. OVA
←→ AHR,
↓ Eosinophils,
←→Neutrophils
51 Balb/C Sensitisation OVA i.p. d0; OVA IN
d12–13; OVA IN d33–34
cf. Saline
↑ AHR,
↑ Eosinophils,
↑ Neutrophils
51,88 Balb/C Sensitisation OVA i.p. d0; OVA IN
d12–13; OVA IN d33–34; dexa-
methasone IN d32–34
cf. OVA
↓ AHR,
↓ Eosinophils,
↓ Neutrophils
51 Balb/C Sensitisation OVA i.p. d0; OVA IN
d12–13; Chlamydia muridarum IN
d14; OVA IN d33–34
cf. OVA
↑ AHR,
↑ Eosinophils,
↑ Neutrophils
51 Balb/C Sensitisation OVA i.p. d0; OVA IN
d12–13; Chlamydia muridarum IN
d14; OVA IN d33–34; dexamethasone
IN d32–34
cf. OVA/cmu
←→AHR,
←→Eosinophils,
←→Neutrophils
51 Balb/C Sensitisation OVA i.p. d0; OVA IN
d12–15
cf. Saline
↑ AHR,
↑ Eosinophils,
↑ Neutrophils
51,88 Balb/C H. influenzae IT d-10; sensitisation
OVA i.p. d0; OVA IN d12–15
cf. OVA
←→ /↓ AHR,
↓ Eosinophils,
↑ Neutrophils
88 Balb/C H. influenzae IT d-10; sensitisation
OVA i.p. d0; OVA in d12–15; dexa-
methasone d13–15
cf. HI OVA
←→AHR,
←→Eosinophils,
←→Neutrophils
51 Balb/C H. influenzae IT d-10; Clarithromycin
d8–d-6; sensitisation OVA i.p. d0; OVA
in d12–15; dexamethasone d13–15
cf. HI Clar OVA
←→AHR,
↓ Eosinophils,
←→Neutrophils
Abbreviations: AHR, airway hyperresponsiveness; Clar, clarithromycin; cf., compared with;
HI, haemophilus influenzae; HDM, house dust mite; OVA, ovalbumin.
Bold entities signify steroid-resistant features in various models.
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technology that is designed to analyse the transcriptional profile
(largely mRNA but also miRNA) of an entire genome. Despite the
mainstream availability of technologically superior approaches,
microarray-based profiling remains as a readily accessible and power-
ful tool in the characterisation of transcriptional responses. Micro-
arrays consist of embedded probes, each representing a gene in a
genome of interest, using fluorescence to quantify the degree of sample
hybridisation to complementary array probes, in which the data
undergoes transformation, normalisation, and multiple test correc-
tions to minimise the chance of false positives and type II errors.
However, microarray-based gene expression profiling is limited as a
pure discovery platform since probe libraries are generated against
databased genes with a strong representation from mRNAs or
transcripts thereof.
Recent advances in sequencing technology have given researchers
unprecedented access to next-generation sequencing as a pure
discovery tool in the field of transcriptomics. Transcriptomics is the
study of the transcriptome, which is the full complement of all RNA
species in a given cell or population of cells. RNA sequencing
(RNA-seq) is an approach that is gaining popularity in disease research
and employs next-generation sequencing technology to map the
genome of a disease state. RNA-seq provides the sequence of RNA
molecules within a sample and relative abundance of each. In contrast
to microarray-based approaches, RNA-seq is not limited to detecting
transcripts represented in a prepared probe library. RNA-seq has the
sensitivity to detect transcripts over six orders of magnitude with low
background noise, which minimises the likelihood of obtaining false
results. RNA-seq has been shown to be highly accurate in determining
gene expression levels with a high level of reproducibility across
technical and biological replicates. This approach has been used to
identify three clusters of asthma endotypes in sputum and blood
samples; first cluster with low pre-bronchodilator FEV1 and high post-
bronchodilator response; second cluster with asthma hospitalisation;
third cluster with normal lung function and lower inhaled steroid
requirements.105 In addition, transcriptomic analysis of severe
asthmatics has identified activated CD8+ T cells compared with
non-severe asthma and healthy controls.106
Interactions of the identified genes from these processes may then
be explored through bioinformatics profiling that allows differentially
expressed genes found within disease states to be visualised, showing
not only interactions between altered genes, but also through the
grouping of genes into molecular processes and pathways using
commercially available platforms such as Ingenuity Pathway Analysis.
The application of GEx microarray and RNA-seq technologies with
subsequent bioinformatics analysis to models of infection-induced,
SSR asthma can facilitate the identification of novel factors and/or
signalling pathways that are potentially underpinning the pathogenesis
and/or development of steroid resistance.107
Translational human studies
The analysis of animal models is a powerful tool for discovery of the
involvement of new pathogenic factors and their potential for
therapeutic targeting. However, in order to ascertain the human
relevance of these findings, the pathways, mechanisms and potential
therapeutic targets identified must be pursued further in clinical
studies. The same factors can be assessed in cells and tissues from
humans where their potential role/s in the target disease can be
assessed, and relationships with infections can be tested.69,87,107 Once
the critical cells and tissues have been identified in vitro studies with
representative cell lines or primary cells can be performed with and
without allergen, infectious or other challenge and the relevant
interventions.108 However, great care needs to be taken during
translation and, ideally, well-characterised patients with the relevant
disease and disease endotype/s are recruited for such studies. Roles for
IL-5 and IL-13 in asthma pathogenesis were discovered using mouse
models and assessment of human tissues.4,5,109 Monoclonal antibodies
for human use were developed against these cytokines and tested in a
cohort of asthma patients in a safety and efficacy trial.4,5 However, the
trials were not designed as treatment trials and the patients were not
tested prior to entering the trials for elevated IL-5 and IL-13, and the
treatments were deemed to have failed as they did not improve patient
symptoms. Upon stratification of patients with high levels of
eosinophilic inflammation despite inhaled glucocorticoid use, anti-
IL-5 treatment (Mepolizumab and Reslizumab) significantly reduced
asthma exacerbations and eosinophil levels.110,111 Mepolizumab is
now FDA approved and Reslizumab is recommended for approval.
This highlights how direct mouse to human clinical translation can
lead to registered new drugs. Furthermore, development of new
techniques, including precision cut lung slicing enables the assessment
of lung function and the effects of drugs in live tissues. Both mouse
and human lung tissues can be interrogated using this
technique.112–114 Comparisons of responses to factors and treatments
in diseased and normal tissues from mouse and human origin using
the same method will facilitate translation of experimental findings.
Infectious exacerbations and other diseases
The studies described above are related to understanding the
pathogenesis of asthma. Asthma and other chronic respiratory diseases
are prone to sporadic acute increases in symptoms termed attacks or
exacerbations. Respiratory infections are the primary cause of these
exacerbations. Mouse models of infectious exacerbations have been
developed whereby infections are induced after AAD is established.115
They enable the investigation of the pathogenesis of infectious
exacerbations in asthma and other chronic respiratory diseases.
In similar ways many other mouse models of other respiratory (for
example, chronic obstructive pulmonary disease, pollution
exposure116–119) and other conditions (for example, colitis, arthritis,
clotting defects118,120,121) have been developed for which there are no
treatments in humans. These models can be interrogated in similar
ways in order to develop new therapies for these diseases.
CONCLUSION AND FUTURE DIRECTIONS
The development of animal models that accurately recapitulate the
hallmark features of human diseases, such as SSR asthma, are rapidly
being developed. They are valuable in identifying and elucidating the
roles of pathogenic factors, identifying new treatment targets and
testing new therapies. Individual factors can be selected from other
studies or from hypothesis-driven research. In relation to the ever
growing array of bioinformatics technology and sequencing events, the
application of these technologies has the capacity to unlock a greater
understanding of SSR asthma and other diseases in conjunction with
representative animal models and identify novel targets and therapeutic
strategies. Data need to be carefully applied to well designed human
studies to validate and translate findings into humans and clinical trials.
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